Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

Amit Bar-Or, Peter A.J. Calabresi, Douglas Arnlod, Clyde Markowitz, Stuart Shafer, Lloyd H. Kasper, Emmanuelle Waubant, Suzanne Gazda, Robert J. Fox, Michael Panzara, Neena Sarkar, Sunil Agarwal, Craig H. Smith

Research output: Contribution to journalArticle

Abstract

We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted; events were limited to mild-to-moderate infusion-associated events, which tended to decrease with subsequent infusions. Infections were also mild or moderate, and none led to withdrawal. Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy.

Original languageEnglish (US)
Pages (from-to)395-400
Number of pages6
JournalAnnals of neurology
Volume63
Issue number3
DOIs
StatePublished - Mar 1 2008

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial'. Together they form a unique fingerprint.

  • Cite this

    Bar-Or, A., Calabresi, P. A. J., Arnlod, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., Sarkar, N., Agarwal, S., & Smith, C. H. (2008). Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Annals of neurology, 63(3), 395-400. https://doi.org/10.1002/ana.21363